Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer

Inclusion Criteria: * Histologically verified squamous cell carcinoma of the head and neck where curatively intended local treatment is not possible. * Measurable or non-measurable disease. * Disease progression during or after first line palliative chemotherapy with cisplatinum or patients with recurrence \< 6 months after primary concomitant chemo-radiotherapy with cisplatinum. * WHO Performance Status 0-2. * Age ≥ 18 years. * Neutrophil count (ANC) ≥ 1.5 x 10\^9/l and platelets ≥ 100 x 10\^9/l. * Normal liver function with bilirubin \< 1.5 x UNL (Upper Normal Limit), no UNL for ALAT with liver metastases. * Creatinin clearance ≥ 50 ml/min. * Signed informed consent. Exclusion Criteria: * Other active malignant disease. * Patients who are considered unable to follow the treatment plan or follow-up visits. * Other serious disease (e.g. severe heart disease, myocardial infarction (MI) within 1 year, active infection). * Any condition or treatment which after the opinion of the investigator may expose the patient to a risk or may influence the purpose of the trial. * Pregnant or lactating women. * Known hypersensitivity towards one or more of the components of the treatment. * Prior treatment with either cetuximab or other inhibitors of EGFR.